Results 151 to 160 of about 766 (168)

Review for "Tagraxofusp in myeloid malignancies"

2023
openaire   +2 more sources

Author response for "Tagraxofusp in myeloid malignancies"

2023
null Antonella Bruzzese, null Enrica Antonia Martino, null Caterina Labanca, null Francesco Mendicino, null Eugenio Lucia, null Virginia Olivito, null Antonino Neri, null Annalisa Imovilli, null Fortunato Morabito, null Ernesto Vigna, null Massimo Gentile   +10 more
openaire   +1 more source

Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm

Leukemia & Lymphoma, 2022
Rocío Díaz Acedo, María Ángeles Domínguez Muñoz, Clara Navajas Laguna, Rosario Morales Camacho, Isabel Simón Pilo, Virgilio Pablo Calama Ruiz-Mateos, Manuel Yébenes Ramírez, María Vahí Sánchez de Medina, Silvia Artacho Criado, Aitana Rodríguez Pérez, María Carmen Couto Caro   +10 more
openaire   +2 more sources

Decision letter for "Tagraxofusp in myeloid malignancies"

2023
openaire   +2 more sources

Expert Opinion on Pharmacotherapy

Expert Opinion on Pharmacotherapy, 2022
Naveen Pemmaraju, Nathaniel R Wilson
exaly  

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2020
Mansour Alfayez, Naveen Pemmaraju, Marina Konopleva   +2 more
exaly  

Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review

Journal of Oncology Pharmacy Practice, 2021
Yazan Samhouri
exaly  

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm

Expert Review of Clinical Pharmacology, 2019
Andrew A Lane, Naveen Pemmaraju, Minas P Economides   +2 more
exaly  

Promising results with tagraxofusp in BPDCN

The Lancet Oncology, 2019
openaire   +2 more sources

Dexamethasone/tagraxofusp

Reactions Weekly
openaire   +1 more source